Suppr超能文献

U22 方案作为评估心房颤动导管消融术后症状改善的指标。

U22 protocol as measure of symptomatic improvement after catheter ablation of atrial fibrillation.

机构信息

Department of Cardiology, Heart Centre, University Hospital , S-901 85 Umeå , Sweden.

出版信息

Ups J Med Sci. 2013 Nov;118(4):240-6. doi: 10.3109/03009734.2013.821190.

Abstract

INTRODUCTION

Left atrial catheter ablation is useful as symptomatic treatment in selected patients with atrial fibrillation (AF). Evaluation requires measurement of arrhythmia-related symptoms. Many of the published protocols have drawbacks and have been used in AF only, with no possible comparison to other ablations that compete for the same resources. U22 is a published protocol that quantifies paroxysmal tachycardia symptoms through scales with 11 answer alternatives, translated into discrete numerical scales 0-10. It has been shown to reflect the clinical improvement after ablation of supraventricular tachycardia. Here we report the use of U22 in measuring improvement after catheter ablation for AF.

MATERIAL AND METHODS

A total of 105 patients underwent first-time ablation for AF and answered U22 and SF-36 forms at baseline and follow-up 304 (SD 121) days after ablation. Independently, the patients underwent a clinical follow-up. All decisions regarding medication and reablation were taken without knowledge of the symptom scores. Results. The U22 scores for well-being, arrhythmia as cause for impaired well-being, derived time-aspect score for arrhythmia, and discomfort during attack detected relevant improvements of symptoms after the ablation. U22 showed larger improvement in patients undergoing only one procedure than in patients who later underwent repeated interventions, thus reflecting the independent clinical decision for reablation.

CONCLUSION

U22 quantifies the symptomatic improvement after AF ablation with adequate internal consistency and construct validity. U22 mirrors aspects of the arrhythmia symptomatology other than SF-36.

摘要

简介

左心房导管消融术对于有症状的心房颤动(AF)患者是一种有效的治疗方法。评估需要测量与心律失常相关的症状。许多已发表的方案都有缺点,仅在 AF 中使用,无法与其他竞争相同资源的消融术进行比较。U22 是一种已发表的方案,通过具有 11 个答案选择的量表来量化阵发性心动过速症状,转化为离散的数值量表 0-10。它已被证明能反映出对室上性心动过速消融后的临床改善。在这里,我们报告了 U22 在测量 AF 导管消融后改善情况中的应用。

材料和方法

共有 105 例患者首次接受 AF 消融治疗,并在消融后 304 天(SD 121)时进行 U22 和 SF-36 问卷调查。独立地,患者接受了临床随访。所有关于药物治疗和再消融的决定都是在不知道症状评分的情况下做出的。结果:U22 在健康状况、心律失常作为健康状况受损的原因、心律失常的衍生时间方面评分以及发作时的不适方面的评分显示出了症状改善。与后来接受重复干预的患者相比,仅接受一次手术的患者 U22 评分的改善更大,这反映了再消融的独立临床决策。

结论

U22 以足够的内部一致性和结构有效性量化了 AF 消融后的症状改善。U22 反映了 SF-36 以外的心律失常症状学方面。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29dd/4190885/ffb918f7c80c/UPS-118-240-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验